TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Eczema Area and Severity Index (EASI) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver hypertrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy in MR and PET/CT assessment of ovarian cancer resectability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain during IUD insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone mineral density of the lower leg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in clinical diagnosis after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: absolute scotoma in central visual field
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: narrowing of peripheral visual field
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: contrast sensitivity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of the lateral-flow urine LAM assay (LF-LAM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of the lateral-flow urine LAM assay (LF-LAM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Failure rate of the lateral-flow urine LAM assay
Endpoint domain: Adverse events/effects
Primary endpoint: Intra abdominal hypertension (HIA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Round Belly Sign
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients Without a Stroke, Systemic Embolism, or Major Bleed
Endpoint domain: Mortality/survival
Primary endpoint: Serum fasting glucose values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Progression of Congestive Heart Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Epithelial Lining Fluid (ELF) Concentration of Nacubactam to Plasma Concentration of Nacubactam Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FFR measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Skills to effectively deal with resident behavioral problems
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in ART adherence percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative rate
Endpoint domain: Adverse events/effects
Primary endpoint: Western Ontario Rotator Cuff Index
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rates of relapse/recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Number of new surgically eligible BCCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in lifestyle characteristics related to NCDs
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Female sexual function index
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Mental health quality of life (QOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Subjective caregiver burden
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Presence of Specific Phobia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of Specific Phobia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the minimum erythemal dose (MED) of ultraviolet radiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: brain lactate concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients participating in screening arms
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Prevalence of SARS-CoV-2 RNA in nasopharyngeal samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Prevalence of anti-SARS-CoV-2 antibodies in blood samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Continuous 24h ambulatory gastric pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: 24h plasma gastrin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of adherence to HF therapies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of IL-1a
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 6-month change in visceral and subcutaneous abdominal fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Occurrence of adverse events - systemic reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of adverse events - local reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of consent to trial participation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pill count values compared between arms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Massachusetts General Hospital Hairpulling Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in National Institute of Mental Health (NIMH) Trichotillomania Severity and Impairment Scales
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Trichotillomania Diagnostic Interview (modified for DSM-5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NEWS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammation level - CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: ET-1 Mediated Constriction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: changes of blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in serum Neutrophil gelatinase-associated lipocalin (NGAL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major morbidities of newborns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve Over the Time Interval From 0 Extrapolated to Infinity (AUC 0-infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analog Score for pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EDSS progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: MS functional composite score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in analgesic use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: First Incidence of stroke
Endpoint domain: Mortality/survival
Primary endpoint: Toxicity and safety
Endpoint domain: Adverse events/effects
Primary endpoint: Lingual strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to relapse of atopic dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Investigators Global Assessment (IGA) of atopic dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pruritus (itch) assessment of atopic dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estimate of 10-year Cardiovascular Disease Risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in adjusted HAM-D scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to DAPT regimen
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Sensitivity and specificity of screening program for preeclampsia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Sensory Attributes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Vaping Delay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of thoracic ducts seen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from major adverse events (MAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: stride and speed walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: respiratory rate/tidal volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Coronary heart disease risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Long-term effectiveness after implantation of MiniArc sling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of subsequent clinical events including subsequent bleeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of health-care resource utilization (HCRU)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Health-care costs associated with bleeding events
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: laboratory-confirmed influenza infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Subjects Exhibiting Pathologic Complete Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cancer and treatment distress (CTXD) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PHQ-8 depression score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of adherence to recommended survivorship preventive care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: MAX-PC Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: FACT-P Scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Participant compliance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Glucose Metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of subjects with new onset GVHD
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects developing NCI Grade 3-4 adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in episodic memory (composite score)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Average Pain Intensity at Rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central monoacylglycerol lipase (MAGL) occupancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postpartum pain evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Esophageal sensory and pain thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in participant perceived fatigue severity
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in the impact of fatigue on daily life
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of patients who are continent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of the Language Environment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Quality of the Child Sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Parenting Interactions with Children
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in self-rated function and ability to be active
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in objective description of function and ability to be active
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Weekly Average Pain Score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Objective response of non-target lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Resolution of ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Lower Extremity Lymphedema Index (LELI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower limb venous hemodynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in BH4 Levels in Cerebral Spinal Fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Neurotransmitter Metabolite Levels in Cerebral Spinal Fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Moderate-Vigorous Physical Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Behavioural Regulation In Exercise Questionnaire (BREQ-2)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Wrist Range of Motion (ROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Mayo Wrist Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thyroid size after intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Adverse Events (AEs) Leading to Discontinuation of Study Drug
Endpoint domain: Adverse events/effects
Primary endpoint: healing of the sinus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ETDRS Visual acuity change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With an Adverse Event of Erythema
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Maximum Plasma Concentration (Cmax) of MK-0873
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alberta Infant Motor Scale (AIMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Segmental Assessment Trunk Control (SATCo)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Supplementation Rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Safety of the FreeStyle Libre Flash Glucose Monitoring System
Endpoint domain: Adverse events/effects
Primary endpoint: Crying times
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Microbiota analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment-emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment-emergent Adverse Events Leading to Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Time to occurrence of Skeletal-related Events (SRE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Relative change (%) in bone-ALP levels from baseline to 4 weeks after last injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinical Global Impression-Scale (CGI-S)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Plasma levels for SB-715992 and Capecitabine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI T2 signal changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual analog scale diary
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants Achieving Rapid Virological Response (RVR) at Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in HCV Viral Load During 24 Hour Following a Single Dose of GSK2336805
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Any Adverse Events (AEs) and Any Serious Adverse Event (SAE) During Treatment Period
Endpoint domain: Adverse events/effects
Primary endpoint: vaginal delivery rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Mean change in intrahepatic triglyceride content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Overactive Bladder Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leiomyoma Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Urine samples for schistosoma haematobium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Stool samples for schistosoma mansoni
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Blood samples for haemoglobin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Retinol level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Transcutaneous oxygen pressure (TcPO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-tumor efficacy of the combination in terms of response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Plasma pharmacokinetic profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ultrasonographic cross-sectional area of rectus femoris
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of milademetan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC) extrapolated to infinity (AUCinf) for milademetan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in urine free cortisol level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Pain assessed with EVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of ipsilateral recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Successful sealing of the LAA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Ischemic stroke, TIA, or Systemic embolism
Endpoint domain: Mortality/survival
Primary endpoint: overall safety profile
Endpoint domain: Adverse events/effects
Primary endpoint: Pain Related Disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Score in Worst Pain Over the Last Month
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Reduction in average daily number of moderate & severe hot flushes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average daily severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement of Clearblue Pregnancy Test result with Duration of Pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Worst Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Interference With Function (Composite Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CCK-release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Patients with Hyperechoic Strands
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients with Hyperechoic Foci
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients with Lobular Contour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients with Cysts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients with Duct Irregularity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients with Ductal Calculi
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of surgeon-performed conventional ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of contrast-enhanced ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of radiation based imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total clearance rate of baseline lesion(s)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean AxV-128/Tc Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circulating CD163 serum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Post kidney transplant mortality
Endpoint domain: Mortality/survival
Primary endpoint: Phenotypic correction of bone marrow colony forming units
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Late xerostomia rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient's subjective report of significant RLS symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes